ArticleFrontiers in immunology2026

SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation

Laura Arosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.